Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Defibrotide · Defitelio, JZP-381

Other · Activator of tissue plasminogen activator (PLAT) · developed by Jazz Pharms

Approved FDA, Mar 2016

JAZZ Developer

1 Registered trials

What is Defibrotide?

Defibrotide is a mixture of single-stranded oligodeoxyribonucleotides derived from porcine intestinal mucosa. It enhances plasmin activity to hydrolyze fibrin clots and increases tissue plasminogen activator and thrombomodulin expression while decreasing von Willebrand factor and plasminogen activator inhibitor-1, thereby protecting endothelial cells and promoting fibrinolysis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Defitelio, JZP-381
Drug type: Other
Targets: tissue plasminogen activator (PLAT) (secondary target), thrombomodulin (THBD) (secondary target), von Willebrand factor (VWF) (secondary target), plasminogen activator inhibitor-1 (SERPINE1) (secondary target)
Mechanism: Activator of tissue plasminogen activator (PLAT)
Pathways: fibrinolysis, endothelial cell protection, platelet adhesion inhibition
Therapy area: Infectious disease, Respiratory
Developer: Jazz Pharms Inc (JAZZ)
FDA status: Approved as Defitelio (March 30, 2016), NDA208114 · FDA label
UNII: L7CHH2B2J0

✅ FDA-approved uses

Hepatic veno-occlusive disease (VOD) with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation

From the indications section of the FDA label (version of Jul 1, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04652115	Phase 2	Covid19	Recruiting	JAZZ

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Covid19

More from Jazz Pharms

Asparaginase Erwinia chrysanthemi FDA approved Calcium, Magnesium, Potassium, And Sodium Oxybates FDA approved Daunorubicin And Cytarabine Liposome FDA approved Lurbinectedin FDA approved Zanidatamab FDA approved CBD-OS Phase 3 Flezurafenib Phase 1 JZP269 Phase 1 JZP926 Phase 2/3 Nabiximols Phase 2 ONC206 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the JAZZ page.

Follow JAZZ, the company behind Defibrotide

See JAZZ's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

JAZZ catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z